Umbilical cord serum therapy in acute ocular chemical burns

ISRCTN ISRCTN08131903
DOI https://doi.org/10.1186/ISRCTN08131903
Secondary identifying numbers N/A
Submission date
04/06/2010
Registration date
05/07/2010
Last edited
06/04/2011
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Injury, Occupational Diseases, Poisoning
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Prof Rasik Vajpayee
Scientific

Centre for Eye Research Australia
University of Melbourne
Royal Victorian Eye and Ear Hospital
32, Gisborne Street, East Melbourne
Victoria
Melbourne
3002
Australia

Email rasikv@unimelb.edu.au

Study information

Study designDouble blind prospective randomised controlled clinical trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Hospital
Study typeTreatment
Participant information sheet Not available in web format, please contact Dr Manik Goel [manikgoel_aiims99@yahoo.com] to request a patient information sheet
Scientific titleEvaluation of umbilical cord serum therapy in acute ocular chemical burns: a prospective, double-blind, randomised controlled trial
Study objectivesThe primary objectives of therapy in a case of acute ocular chemical burns are promotion of epithelialisation, reduction of inflammation, support of the reparative processes and prevention of complications. The standard medical treatment used in acute ocular chemical burns comprises of topical steroids, topical antibiotics, mydriatic cycloplegic, anti-glaucoma therapy, citrate and ascorbate. Autologous serum drops have been shown to be effective in the treatment of various ocular surface disorders including neurotrophic keratitis, severe dry eye, persistent epithelial defects and recurrent corneal erosions. Umbilical cord serum has been shown to be safe and effective in the treatment of neurotrophic keratitis, dry eye syndrome and persistent epithelial defects.

Both autologous serum and umbilical cord serum owe their efficacy to the presence of various growth factors like epidermal growth factor (EGF), acidic and basic fibroblast growth factor (FGF), platlet-derived growth factor, hepatocyte growth factor, vitamin A, transforming growth factor ß (TGF-ß), substance P, IGF-1 (insulin like growth factor-1), nerve growth factor (NGF), fibronectin and serum antiproteases such as a2 macroglobulin. The concentrations of EGF, TGF-ß and NGF are several times higher in umbilical cord serum than peripheral blood serum. In the present study we tested the hypothesis, that umbilical cord serum with its higher concentration of these growth factors may promote an early healing of the ocular surface in cases of chemical burns.
Ethics approval(s)All India Institute of Medical Sciences, New Delhi, India approved on the 15th of September 2005
Health condition(s) or problem(s) studiedAcute chemical ocular burns
Intervention1. Patients were started on standard medical therapy consisting of:
1.1. Topical ofloxacin hydrochloride 0.3% 6-hourly
1.2. Topical prednisolone acetate 1% 2-hourly
1.3. Topical homatropine 2% three times daily (tds)
1.4. Topical ascorbate 10% 2-hourly
1.5. Topical citrate 10% 2-hourly
1.6. Oral vitamin C 500 mg four times daily (qid)
1.7. Preservative free topical lubricants 2-hourly
1.8. Topical anti-glaucoma medications (if required) in the form of timolol maleate eye drops 0.5% bid and/or oral acetazolamide 250 mg tds

2. Patients were then divided into three groups:
2.1. Group I received 20% umbilical cord serum drops 10 times a day
2.2. Group II received 20% autologous serum drops 10 times a day
2.3. Group III received artificial tear drops (0.5% hydroxypropylmethylcellulose and 0.3% glycerin) 10 times a day
Intervention typeOther
Primary outcome measurePatients were followed up on day 1, day 3, day 7, day 14, day 21 and at the end of 1 month, 2 months and 3 months. Total duration of follow up in all three groups was 3 months.
Parameters assessed were at each follow-up included:
1. Pain score
2. Best corrected visual acuity
3. Limbal ischaemia
4. Epithelial defect
5. Corneal clarity and vascularisation
6. Tear film status (Schirmer, TBUT)
7. Intraocular pressure (IOP)
8. Symblepharon formation
Secondary outcome measuresComplications arising from injury and/or treatment
Overall study start date01/09/2005
Completion date01/07/2007

Eligibility

Participant type(s)Patient
Age groupAdult
SexBoth
Target number of participants33 eyes of 32 patients
Key inclusion criteria1. Patients with acute ocular chemical burns (grade III, IV and V according to Dua classification) presenting within three weeks of injury
2. Either sex, aged 16 - 50 years
Key exclusion criteria1. Patients with grade I, II and VI injury
2. Impending perforation
Date of first enrolment01/09/2005
Date of final enrolment01/07/2007

Locations

Countries of recruitment

  • Australia
  • India

Study participating centre

Centre for Eye Research Australia
Melbourne
3002
Australia

Sponsor information

Dr Rajendra Prasad Centre for Ophthalmic Sciences (India)
Hospital/treatment centre

Ansari Nagar
New Delhi
3002
India

Email rasikv@unimelb.edu.au
ROR logo "ROR" https://ror.org/02dwcqs71

Funders

Funder type

Hospital/treatment centre

Dr RP Centre for Ophthalmic Sciences (India) - Hospital infrastructure and resources

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results 25/02/2011 Yes No